Abacus FCF Advisors LLC Takes $2.70 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Abacus FCF Advisors LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 27,699 shares of the medical equipment provider's stock, valued at approximately $2,703,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the 4th quarter worth approximately $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter worth $37,000. Parkside Financial Bank & Trust boosted its stake in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. UMB Bank n.a. grew its position in Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after acquiring an additional 381 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in shares of Lantheus in the fourth quarter worth about $125,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of LNTH traded up $0.33 during trading hours on Wednesday, hitting $80.75. The company's stock had a trading volume of 1,120,819 shares, compared to its average volume of 1,007,555. The company has a market cap of $5.59 billion, a price-to-earnings ratio of 13.44 and a beta of 0.11. The business has a 50 day simple moving average of $89.43 and a two-hundred day simple moving average of $91.54. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the firm earned $1.69 earnings per share. Research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director now owns 318,650 shares of the company's stock, valued at $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,068 shares of company stock worth $3,008,051. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus currently has an average rating of "Buy" and an average price target of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.